Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine.
In a study evaluating the efficacy and safety of lansoprazole to prevent the relapse of erosive esophagitis (EE), 206 of 241 patients (85%) healed after open-label treatment with lansoprazole 30 mg once daily for 8 weeks and received double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily for up to 1 year. At 1 year, 67% of lansoprazole-treated and 13% of ranitidine-treated patients remained healed (P<0.001). Lansoprazole-treated patients experienced significantly greater symptom relief (P<0.001), and, if asymptomatic at entry into the maintenance phase, remained asymptomatic for significantly longer than ranitidine-treated patients (P<0.001). Symptom status correlated with healing (P=0.001), supporting the symptom-directed management of EE. Both treatments were well tolerated and no unexpected events occurred. Daily therapy with lansoprazole to prevent the relapse of EE is effective, well tolerated, and superior to ranitidine in the maintenance of healing and symptom relief.
Peura
David A
DA
University of Virginia Health System, Charlottesville, VA 22908-0708, USA. dap8v@virginia.edu
Freston
James W
JW
Haber
Marian M
MM
Kovacs
Thomas O
TO
Hunt
Barbara
B
Atkinson
Stuart
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004941:Esophagitis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D011899:Ranitidine / Q000008:administration & dosage* / Q000009:adverse effects; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014945:Wound Healing / Q000187:drug effects; D055815:Young Adult
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D011899:Ranitidine